01721nas a2200229   4500008004100000022001400041245003600055210003500091260009000126300001200216490000700228520101400235653002201249653000901271653002001280653001701300653002001317100002601337700002901363700002701392856007201419       2010                        eng d  a1354-377600aAntifungal agents, WO20090257330 aAntifungal agents WO2009025733  aTELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLANDbINFORMA HEALTHCAREcJAN  a137-1430 v203 a<p>Background: The incidence and prevalence of serious mycoses continues to be a public health problem. These infections are an important cause of morbidity and mortality, especially in immunocompromised patients. The present patent deals with isolation and characterization of a `pure' mixture of two novel isoxazolidinone-containing natural products from two new fungal strains. They have the partial structure of secalonic acid and show very good antifungal activity in mammals and plants and also synergism with other active ingredients. Objective: To analyze the activity of the isoxazolidinone-containing compounds in the present patent. Methods: To review the discovery and development of antifungal compounds in general and secalonic acid related compounds in particular. Conclusion: The research of Parish and collaborators at Merck and Co. has isolated novel antifungal compounds with a new mode of action. These molecules may be considered potential antifungal leads for further clinical study.</p>10aAntifungal agents10aCaFT10aisoxazolidinone10aparnafungins10asecalonic acids1 aSudhir, Pore, Vandana1 aRanan, Deshpande, Sunita1 aGanpat, Aher, Nilkanth  uhttps://library.ncl.res.in/content/antifungal-agents-wo2009025733-0